Astaxanthin protects primary hippocampal neurons against noxious effects of A β-oligomers

Neural Plasticity

Volumn 2016, Issue , 2016, Pages

  Lobos, Pedro ^a   Bruna, Barbara ^a   Cordova, Alex ^a   Barattini, Pablo ^a   Galáz, Jose Luis ^a   Adasme, Tatiana ^a   Hidalgo, Cecilia ^a   Muñoz, Pablo ^b   Paula Lima, Andrea ^a,c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DE VALPARAÍSO   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ASTAXANTHIN; HYDROGEN PEROXIDE; MESSENGER RNA; OLIGOMER; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC4; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); ANTIOXIDANT; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NFATC4 PROTEIN, RAT; PEPTIDE FRAGMENT; XANTHOPHYLL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE TRANSLOCATION; HIPPOCAMPUS; HIPPOCAMPUS NERVE CELL; MITOCHONDRION; NERVE CELL; NEUROPROTECTION; NONHUMAN; PLASMID; RAT; ANIMAL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HIPPOCAMPUS; HYDROGEN PEROXIDE; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NFATC TRANSCRIPTION FACTORS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; XANTHOPHYLLS;

EID: 84961907099     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2016/3456783     Document Type: Article

References (79)

1. C. Haass and D. J. Selkoe, "Soluble protein oligomers in neurodegeneration: lessons from the Alzheimers amyloid-peptide, " Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101-112, 2007.
2. Y. Gong, L. Chang, K. L. Viola, et al., "Alzheimers diseaseaffected brain: presence of oligomeric A ligands (ADDLs) suggests amolecular basis for reversible memory loss, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10417-10422, 2003.
3. L. Forny-Germano, N. M. Lyra e Silva, A. F. Batista, et al., "Alzheimers disease-like pathology induced by amyloid-oligomers in nonhuman primates, " The Journal of Neuroscience, vol. 34, no. 41, pp. 13629-13643, 2014.
4. S. T. Ferreira, M. V. Lourenco, M. M. Oliveira, and F. G. De Felice, "Soluble amyloid-oligomers as synaptotoxins leading to cognitive impairment in Alzheimers disease, " Frontiers in Cellular Neuroscience, vol. 9, article 191, 2015.
5. D. A. Butterfield, A. M. Swomley, and R. Sultana, "Amyloid-peptide (1-42)-induced oxidative stress in alzheimer disease: importance in disease pathogenesis and progression, " Antioxidants and Redox Signaling, vol. 19, no. 8, pp. 823-835, 2013.
6. K. J. Barnham, C. L. Masters, and A. I. Bush, "Neurodegenerative diseases and oxidative stress, " Nature Reviews Drug Discovery, vol. 3, no. 3, pp. 205-214, 2004.
7. P. B. Campos, B. S. Paulsen, and S. K. Rehen, "Accelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species, " Frontiers in Aging Neuroscience, vol. 6, article 292, 2014.
8. K. N. Green and F. M. LaFerla, "Linking calcium to A and Alzheimers disease, " Neuron, vol. 59, no. 2, pp. 190-194, 2008.
9. F. G. De Felice, P. T. Velasco, M. P. Lambert, et al., "A oligomers induce neuronal oxidative stress through an N-methyl-Daspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine, " The Journal of Biological Chemistry, vol. 282, no. 15, pp. 11590-11601, 2007.
10. A. C. Paula-Lima, J. Brito-Moreira, and S. T. Ferreira, "Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimers disease, " Journal of Neurochemistry, vol. 126, no. 2, pp. 191-202, 2013.
11. G. M. Shankar, B. L. Bloodgood, M. Townsend, D. M. Walsh, D. J. Selkoe, and B. L. Sabatini, "Natural oligomers of the Alzheimer amyloid-protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway, " Journal of Neuroscience, vol. 27, no. 11, pp. 2866-2875, 2007.
12. M. P. Parsons and L. A. Raymond, "Extrasynaptic NMDA receptor involvement in central nervous system disorders, " Neuron, vol. 82, no. 2, pp. 279-293, 2014.
13. A. Sebollela, L. Freitas-Correa, F. F. Oliveira, et al., "Amyloid-oligomers induce differential gene expression in adult human brain slices, " The Journal of Biological Chemistry, vol. 287, no. 10, pp. 7436-7445, 2012.
14. C. Barucker, A. Harmeier, J. Weiske, et al., "Nuclear translocation uncovers the amyloid peptide a42 as a regulator of gene transcription, " Journal of Biological Chemistry, vol. 289, no. 29, pp. 20182-20191, 2014.
15. L. C. Reese and G. Taglialatela, "A role for calcineurin in Alzheimers disease, " Current Neuropharmacology, vol. 9, no. 4, pp. 685-692, 2011.
16. H. Wu, H. Niu, A. Shao, et al., "Astaxanthin as a potential neuroprotective agent for neurological diseases, " Marine Drugs, vol. 13, no. 9, pp. 5750-5766, 2015.
17. S. D. Rege, T. Geetha, T. L. Broderick, and J. R. Babu, "Resveratrol protects amyloid-induced oxidative damage and memory associated proteins in H19-7 hippocampal neuronal cells, " Current Alzheimer Research, vol. 12, no. 2, pp. 147-156, 2015.
18. M. Kurashige, E. Okimasu, M. Inoue, and K. Utsumi, "Inhibition of oxidative injury of biological membranes by astaxanthin, " Physiological Chemistry and Physics and Medical NMR, vol. 22, no. 1, pp. 27-38, 1990.
19. E. Hernandez-Marin, A. Barbosa, and A. Martinez, "The metal cation chelating capacity of astaxanthin. Does this have any influence on antiradical activity?" Molecules, vol. 17, no. 1, pp. 1039-1054, 2012.
20. M. O. M. Tso and T.-T. Lam, "Method of retarding and ameliorating central nervous system and eye damage, " United States Patent US 5527533, 1996.
21. N. Shimidzu, M. Goto, and W. Miki, "Carotenoids as singlet oxygen quenchers in marine organisms, " Fisheries Science, vol. 62, no. 1, pp. 134-137, 1996.
22. K. Nakagawa, T. Kiko, T. Miyazawa, et al., "Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes, " British Journal of Nutrition, vol. 105, no. 11, pp. 1563-1571, 2011.
23. H. Shen, C.-C. Kuo, J. Chou, et al., "Astaxanthin reduces ischemic brain injury in adult rats, " The FASEB Journal, vol. 23, no. 6, pp. 1958-1968, 2009.
24. M. Ichida and T. Finkel, "Ras regulates NFAT3 activity in cardiac myocytes, " The Journal of Biological Chemistry, vol. 276, no. 5, pp. 3524-3530, 2001.
25. A. C. Paula-Lima, T. Adasme, C. Sanmartin, et al., "Amyloid-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF, " Antioxidants & Redox Signaling, vol. 14, no. 7, pp. 1209-1223, 2011.
26. C. D. SanMartin, A. C. Paula-Lima, C. Hidalgo, and M. T. Nunez, "Sub-lethal levels of amyloid-peptide oligomers decrease non-transferrin-bound iron uptake and do not potentiate iron toxicity in primary hippocampal neurons, " BioMetals, vol. 25, no. 4, pp. 805-813, 2012.
27. C. D. SanMartin, A. C. Paula-Lima, A. Garcia, et al., "Ryanodine receptor-mediated Ca2+ release underlies iron-induced mitochondrial fission and stimulates mitochondrial Ca2+ uptake in primary hippocampal neurons, " Frontiers in Molecular Neuroscience, vol. 7, article 13, 2014.
28. A. C. Paula-Lima, F. G. De Felice, J. Brito-Moreira, and S. T. Ferreira, "Activation ofGABAA receptors by taurine andmuscimol blocks the neurotoxicity of-amyloid in rat hippocampal and cortical neurons, " Neuropharmacology, vol. 49, no. 8, pp. 1140-1148, 2005.
29. A. C. Paula-Lima, M. A. Tricerri, J. Brito-Moreira, et al., "Human apolipoprotein A-I binds amyloid-and prevents A-induced neurotoxicity, " International Journal of Biochemistry and Cell Biology, vol. 41, no. 6, pp. 1361-1370, 2009.
30. V. V. Belousov, A. F. Fradkov, K. A. Lukyanov, et al., "Genetically encoded fluorescent indicator for intracellular hydrogen peroxide, " Nature Methods, vol. 3, no. 4, pp. 281286, 2006.
31. M. W. Pfaffl, "A new mathematical model for relative quantification in real-time RT-PCR, " Nucleic Acids Research, vol. 29, no. 9, article e45, 2001.
32. Y. Lu, T. Xie, X.-X. He, et al., "Astaxanthin rescues neuron loss and attenuates oxidative stress induced by amygdala kindling in adult rat hippocampus, " Neuroscience Letters, vol. 597, pp. 49-53, 2015.
33. X. Zhou, F. Zhang, X. Hu, et al., "Inhibition of inflammation by astaxanthin alleviates cognition deficits in diabetic mice, " Physiology & Behavior, vol. 151, pp. 412-420, 2015.
34. B. J. Tabner, J. Mayes, and D. Allsop, "Hypothesis: soluble A oligomers in association with redox-active metal ions are the optimal generators of reactive oxygen species in Alzheimers disease, " International Journal of Alzheimers Disease, vol. 2011, Article ID 546380, 6 pages, 2011.
35. T. Ma, C. A. Hoeffer, H. Wong, et al., "Amyloid-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide, " Journal of Neuroscience, vol. 31, no. 15, pp. 5589-5595, 2011.
36. H. Bading, "Nuclear calcium signalling in the regulation of brain function, " Nature Reviews Neuroscience, vol. 14, no. 9, pp. 593-608, 2013.
37. P. L. Greer and M. E. Greenberg, "From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function, " Neuron, vol. 59, no. 6, pp. 846-860, 2008.
38. M. Cavazzini, T. Bliss, and N. Emptage, "Ca2+ and synaptic plasticity, " Cell Calcium, vol. 38, no. 3-4, pp. 355-367, 2005.
39. F. M. LaFerla, "Calcium dyshomeostasis and intracellular signalling in Alzheimers disease, " Nature Reviews Neuroscience, vol. 3, no. 11, pp. 862-872, 2002.
40. N. Schwartz, A. Schohl, and E. S. Ruthazer, "Neural activity regulates synaptic properties and dendritic structure in vivo through calcineurin/NFAT signaling, " Neuron, vol. 62, no. 5, pp. 655-669, 2009.
41. J. D. Ulrich, M.-S. Kim, P. R. Houlihan, et al., "Distinct activation properties of the nuclear factor of activated T-cells (NFAT) isoforms NFATc3 and NFATc4 in neurons, " The Journal of Biological Chemistry, vol. 287, no. 45, pp. 37594-37609, 2012.
42. H.-Y. Wu, E. Hudry, T. Hashimoto, et al., "Amyloid induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation, " Journal of Neuroscience, vol. 30, no. 7, pp. 2636-2649, 2010.
43. E. Hudry, H.-Y. Wu, M. Arbel-Ornath, et al., "Inhibition of the NFAT pathway alleviates amyloid beta neurotoxicity in a mouse model of Alzheimers disease, " The Journal of Neuroscience, vol. 32, no. 9, pp. 3176-3192, 2012.
44. H. M. Abdul, M. A. Sama, J. L. Furman, et al., "Cognitive decline in Alzheimers disease is associated with selective changes in Calcineurin/NFAT signaling, " Journal of Neuroscience, vol. 29, no. 41, pp. 12957-12969, 2009.
45. H. M. Abdul, J. L. Furman, M. A. Sama, D. M. Mathis, and C. M. Norris, "NFATs and Alzheimers disease, " Molecular and Cellular Pharmacology, vol. 2, no. 1, pp. 7-14, 2010.
46. T. Adasme, P. Haeger, A. C. Paula-Lima, et al., "Involvement of ryanodine receptors in neurotrophin-induced hippocampal synaptic plasticity and spatial memory formation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 7, pp. 3029-3034, 2011.
47. D. Baglietto-Vargas, Y. Chen, D. Suh, et al., "Short-termmodern life-like stress exacerbates A-pathology and synapse loss in 3xTg-AD mice, " Journal of Neurochemistry, vol. 134, no. 5, pp. 915-926, 2015.
48. C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones, "Alzheimers disease, "TheLancet, vol. 377, no. 9770, pp. 1019-1031, 2011.
49. C. Reitz and R. Mayeux, "Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers, " Biochemical Pharmacology, vol. 88, no. 4, pp. 640-651, 2014.
50. F. Di Domenico, E. Barone, M. Perluigi, and D. A. Butterfield, "Strategy to reduce free radical species in Alzheimers disease: an update of selected antioxidants, " Expert Review of Neurotherapeutics, vol. 15, no. 1, pp. 19-40, 2015.
51. C. R. Giordano, L. J. Terlecky, A. Bollig-Fischer, P. A. Walton, and S. R. Terlecky, "Amyloid-neuroprotection mediated by a targeted antioxidant, " Scientific Reports, vol. 4, article4983, 2014.
52. C. D. SanMartin, T. Adasme, C. Hidalgo, and A. C. Paula-Lima, "The antioxidant N-acetylcysteine prevents the mitochondrial fragmentation induced by soluble amyloid-peptide oligomers, " Neurodegenerative Diseases, vol. 10, no. 1-4, pp. 34-37, 2012.
53. B. P. Hubbard and D. A. Sinclair, "Small molecule SIRT1 activators for the treatment of aging and age-related diseases, " Trends in Pharmacological Sciences, vol. 35, no. 3, pp. 146-154, 2014.
54. L. Shen and H.-F. Ji, "Vitamin E: supplement versus diet in neurodegenerative diseases, " Trends inMolecularMedicine, vol. 18, no. 8, pp. 443-445, 2012.
55. T. Persson, B. O. Popescu, and A. Cedazo-Minguez, "Oxidative stress in Alzheimers disease: why did antioxidant therapy fail?" OxidativeMedicine and Cellular Longevity, vol. 2014, Article ID 427318, 11 pages, 2014.
56. M. Gammone, G. Riccioni, and N. D'Orazio, "Marine carotenoids against oxidative stress: effects on human health, " Marine Drugs, vol. 13, no. 10, pp. 6226-6246, 2015.
57. S. Dodd, O. Dean, D. L. Copolov, G. S. Malhi, and M. Berk, "N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility, " Expert Opinion on BiologicalTherapy, vol. 8, no. 12, pp. 1955-1962, 2008.
58. O. Dean, F. Giorlando, and M. Berk, "N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action, " Journal of Psychiatry and Neuroscience, vol. 36, no. 2, pp. 78-86, 2011.
59. R. Bull, J. P. Finkelstein, A. Humeres, M. I. Behrens, and C. Hidalgo, "Effects of ATP, Mg2+, and redox agents on the Ca2+ dependence of RyR channels from rat brain cortex, " American Journal of Physiology-Cell Physiology, vol. 293, no. 1, pp. C162-C171, 2007.
60. Q. Huang, C. D. Aluise, G. Joshi, et al., "Potential in vivo amelioration by N-Acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment, " Journal of Neuroscience Research, vol. 88, no. 12, pp. 2618-2629, 2010.
61. S. Franceschelli, M. Pesce, A. Ferrone, et al., "Astaxanthin treatment confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide reducing O2-production, " PLoS ONE, vol. 9, no. 2, Article ID e88359, 2014.
62. E. Rodrigues, L. R. B. Mariutti, and A. Z. Mercadante, "Scavenging capacity of marine carotenoids against reactive oxygen and nitrogen species in a membrane-mimicking system, " Marine Drugs, vol. 10, no. 8, pp. 1784-1798, 2012.
63. Y. Ni, M. Nagashimada, F. Zhuge, et al., "Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: a comparison with vitamin E, " Scientific Reports, vol. 5, Article ID 17192, 2015.
64. X. Wen, A. Huang, J. Hu, et al., "Neuroprotective effect of astaxanthin against glutamate-induced cytotoxicity in HT22 cells: involvement of the Akt/GSK-3 pathway, " Neuroscience, vol. 303, pp. 558-568, 2015.
65. C. L. L. Saw, A. Y. Yang, Y. Guo, and A.-N. T. Kong, "Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway, " Food and Chemical Toxicology, vol. 62, pp. 869-875, 2013.
66. R. Brigelius-Flohe and L. Flohe, "Basic principles and emerging concepts in the redox control of transcription factors, " Antioxidants and Redox Signaling, vol. 15, no. 8, pp. 2335-2381, 2011.
67. C. Li, P. Hossieny, B. J. Wu, A. Qawasmeh, K. Beck, and R. Stocker, "Pharmacologic induction of heme oxygenase-1, " Antioxidants and Redox Signaling, vol. 9, no. 12, pp. 2227-2239, 2007.
68. M. M. Al-Amin, S. Akhter, A. T. Hasan, et al., "The antioxidant effect of astaxanthin is higher in young mice than aged: a region specific study on brain, " Metabolic Brain Disease, vol. 30, no. 5, pp. 1237-1246, 2015.
69. J.-P. Yuan, J. Peng, K. Yin, and J.-H. Wang, "Potential healthpromoting effects of astaxanthin: a high-value carotenoid mostly from microalgae, " Molecular Nutrition and Food Research, vol. 55, no. 1, pp. 150-165, 2011.
70. C.-H. Chang, C.-Y. Chen, J.-Y. Chiou, R. Y. Peng, and C.-H. Peng, "Astaxanthine secured apoptotic death of PC12 cells induced by-amyloid peptide 25-35: its molecular action targets, " Journal of Medicinal Food, vol. 13, no. 3, pp. 548-556, 2010.
71. H.-Q. Wang, X.-B. Sun, Y.-X. Xu, H. Zhao, Q.-Y. Zhu, and C.-Q. Zhu, "Astaxanthin upregulates heme oxygenase-1 expression through ERK1/2 pathway and its protective effect against beta-amyloid-induced cytotoxicity in SH-SY5Y cells, " Brain Research, vol. 1360, pp. 159-167, 2010.
72. I. Bezprozvanny and M. P. Mattson, "Neuronal calcium mishandling and the pathogenesis of Alzheimers disease, " Trends in Neurosciences, vol. 31, no. 9, pp. 454-463, 2008.
73. M. J. Berridge, "Calcium hypothesis of Alzheimers disease, " Pflugers Archiv European Journal of Physiology, vol. 459, no. 3, pp. 441-449, 2010.
74. C. Hidalgo, "Cross talk between Ca2+ and redox signalling cascades in muscle and neurons through the combined activation of ryanodine receptors/Ca2+ release channels, " Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 360, no. 1464, pp. 2237-2246, 2005.
75. J. J. Marengo, C. Hidalgo, and R. Bull, "Sulfhydryl oxidation modifies the calcium dependence of ryanodine-sensitive calcium channels of excitable cells, " Biophysical Journal, vol. 74, no. 3, pp. 1263-1277, 1998.
76. M. Kelliher, J. Fastbom, R. F. Cowburn, et al., "Alterations in the ryanodine receptor calcium release channel correlate with Alzheimers disease neurofibrillary and-amyloid pathologies, " Neuroscience, vol. 92, no. 2, pp. 499-513, 1999.
77. A. C. Paula-Lima, T. Adasme, and C. Hidalgo, "Contribution of Ca2+ release channels to hippocampal synaptic plasticity and spatial memory: potential redox modulation, " Antioxidants & Redox Signaling, vol. 21, no. 6, pp. 892-914, 2014.
78. A. Mukherjee and C. Soto, "Role of calcineurin in neurodegeneration produced by misfolded proteins and endoplasmic reticulum stress, " Current Opinion in Cell Biology, vol. 23, no. 2, pp. 223-230, 2011.
79. F. Liu, I. Iqbal-Grundke, K. Iqbal, Y. Oda, K. Tomizawa, and C.-X. Gong, "Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain, "The Journal of Biological Chemistry, vol. 280, no. 45, pp. 37755-37762, 2005.